Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:07:08.324Z.
Consensus retrieved: 2026-10-06T10:36:07.270Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:07:08.324Z.
Quote observation: 2026-10-06T16:05:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a08bb0e768e445b647833b1fa03ab76594e1458f06569fc43a1aa259a4caca38
Forward PE Ratio (N/A) = Dated Quote Price ($12.61) / Consensus Forward EPS ($-1.72)
FORWARD PE RATIO
N/A
Contineum Therapeutics, Inc.
Market Cap
$474.25M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | $474.25M | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.87M | N/A |
| Cerus Corporation (CERS)vs › | $472.58M | N/A |
| Kamada Ltd. (KMDA)vs › | $472.48M | 17.15 |
| Arvinas, Inc. (ARVN)vs › | $479.06M | N/A |
| NRC Health (NRC)vs › | $462.12M | 23.30 |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.85M | 25.17 |
| Evolus, Inc. (EOLS)vs › | $490.62M | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $450.48M | N/A |
| Oculis Holding AG (OCS)vs › | $498.55M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $12.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.72 | $-1.77 – $-1.62 | 5 | n/m |
| 2027-12-31 | $-1.99 | $-2.23 – $-1.73 | 5 | n/m |
| 2028-12-31 | $-1.98 | $-1.98 – $-1.98 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
